TABLE 1.

Summary of the simulation scenarios in this manuscript.

(I) Simulation scenarios for specific populations with dosage regimen A
Caucasian healthy population (20–50 years)
Chinese healthy population (20–50 years)
Sim-cirrhosis CP-A populations (20–50 and 65–70 years)
Sim-cirrhosis CP-B populations (20–50 and 65–70 years)
Sim-cirrhosis CP-C populations (20–50 and 65–70 years)
Sim-renal-GFR-30–60 populations (20–50, 65–75 and 75–85 years)
Sim-renal-GFR-less-30 populations (20–50, 65–75 and 75–85 years)
Paediatric populations (0–0.5, 0.5–2, 2–6, 6–12, 12–17 years)
Pregnant population (13, 25, 37 gestational weeks)
Geriatric populations (65–75, 75–85, and 85–95 years)
(II) Simulation scenarios of potential drug drug interactions
Inhibitor	Treatment (days)	Dose regimen	HCQ dosage regimen (treatment)
Gemfibrozil (strong CYP2C8 inhibitor)	12	600 mg BID	Regimen A (D 3 - D 7)
Quinidine (strong CYP2D6 inhibitor)	12	200 mg QD	Regimen A (D 3 - D 7)
ritonavir (strong CYP3A4 inhibitor and weak CYP2D6 inhibitor)	12	100 mg QD	Regimen A (D 3 - D 7)